cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Dimethaid gets new name, sells head office, embraces new focus
October 25th, 2005
Shareholders of Dimethaid Research, Inc., (DMX) have approved the change of the company's name to Nuvo Research, Inc., at its annual and special meeting. The company also announced that it has sold its head office in Markham, Ontario. "We are excited about our future," said Dan Chicoine, chairman of Nuvo Research. "We have adopted a new strategic direction to develop and commercialize our innovative therapeutic products. The change in name is a clear signal that we have changed as a company. Nuvo will now focus on early-stage drug research and development and effective commercialization of these efforts." Dr. Henrich Guntermann,...
Source: cancer weekly (2005-10-25)
|
